ArticleCNS neuroscience & therapeutics2024

Spectrum of psychiatric adverse reactions to cyclin-dependent kinases 4/6 inhibitors: A pharmacovigilance analysis of the FDA adverse event reporting system.

Zhijun Xiao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.